SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (301)12/23/1998 4:21:00 PM
From: John Patterson  Read Replies (2) | Respond to of 712
 
George,
Murphy says sales are about 600K/weekly now. Our cath lab has switched over exclusively to Integrilin. A CVS surgeon I work with was discussing sales with one of the S-P reps and he said they were booming. Cor seems to be taking market share from CNTO with Aggrastat a distant 3rd.



To: aknahow who wrote (301)12/23/1998 4:45:00 PM
From: Robert Mayo  Read Replies (2) | Respond to of 712
 
FYI, I think CORR is presenting at the H&Q Biotech conference on Tuesday, 12 January. I wouldn't be surprised to get a little run-up before that in anticipation of a good sales report on Integrilin.

Bob


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News